JAMA - Journal of the American Medical Association This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Uterine Fibroids
This JAMA Insights in the Women ’s Health series discusses the incidence, diagnosis, and treatment of uterine fibroids. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 10, 2024 Category: General Medicine Source Type: research

Consortium Authors and Nonauthor Collaborators Added
The Original Investigation titled “Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection,” published in the June 13, 2023, issue of JAMA, has been corrected to include additional consortium authors and nonauthor collaborator names in a supplement. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 10, 2024 Category: General Medicine Source Type: research

Including Pregnant and Lactating Women in Clinical Research
This Viewpoint summarizes a new report from the National Academies of Sciences, Engineering, and Medicine that encourages the inclusion of pregnant and lactating individuals in clinical research. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 10, 2024 Category: General Medicine Source Type: research

Data Checks Before Registering Study Protocols for Health Care Database Analyses
This Viewpoint discusses the challenges involved with secondary health care data collection vs primary data collection and provides a list of suggested data checks before registration of a study protocol using secondary data. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 8, 2024 Category: General Medicine Source Type: research

Systemic Lupus Erythematosus
This review summarizes current evidence regarding the diagnosis, treatment, and prognosis of systemic lupus erythematosus. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 8, 2024 Category: General Medicine Source Type: research

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)
This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 8, 2024 Category: General Medicine Source Type: research

Cardiac Function Before Sepsis and Clinical Outcomes
This cohort study characterizes heterogeneity in cardiac function prior to sepsis and describes associations with hospitalization outcomes and mortality. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 8, 2024 Category: General Medicine Source Type: research

Error in Conflict of Interest Disclosure Statements
In several JAMA articles published in 2022 and 2023, an incorrect institution was published in Dr Califf ’s conflict of interest disclosure statements: the Center for Policy Analysis on Trade and Health should have been listed as the Critical Path Institute. The articles have been corrected online. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 8, 2024 Category: General Medicine Source Type: research

Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening
This meta-analysis of 41 randomized clinical trials of cancer screening compares cancer-specific mortality with stage III-IV cancer as end points. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 7, 2024 Category: General Medicine Source Type: research

Late-Stage Cancer End Points to Speed Cancer Screening Clinical Trials —Not So Fast
In this issue of JAMA, Feng et al studied whether late-stage cancer (ie, stage III or stage IV cancer), rather than cancer-specific mortality, was an acceptable alternative end point in clinical trials of cancer screening. The authors analyzed 41 clinical trials conducted in Europe, North America, and Asia, combining the data overall and according to cancer type. They evaluated the association between incidence of stage III-IV cancer and cancer-specific mortality in and across the selected studies. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 7, 2024 Category: General Medicine Source Type: research

Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval
This study aims to determine whether cancer drugs granted accelerated approval from the US Food and Drug Administration ultimately demonstrate clinical benefit and to evaluate the basis of conversion to regular approval. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 7, 2024 Category: General Medicine Source Type: research

Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI
This preliminary descriptive report compares the rates of detecting high- and low-grade prostate cancer in men invited for prostate cancer screening vs those not invited to undergo prostate cancer screening. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 6, 2024 Category: General Medicine Source Type: research

A Pragmatic Approach to Prostate Cancer Screening
The introduction of prostate-specific antigen (PSA) –based screening for prostate cancer in the early 1990s was followed by a nearly 2-decade long decline in prostate cancer metastasis and mortality. However, clinical trial data revealed that screening was associated with substantial harms. Under the traditional clinical approach in which elevated serum PSA triggered prostate biopsy, roughly 1 in 5 screened men underwent biopsies, with more than 75% found to be negative and a majority of positive biopsies harboring low-grade, clinically insignificant cancers. Prostate biopsies are uncomfortable for patients and carry a r...
Source: JAMA - Journal of the American Medical Association - April 6, 2024 Category: General Medicine Source Type: research

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 6, 2024 Category: General Medicine Source Type: research

How Generative AI Done Right Could Help Democratize Health Care
This Medical News article is an interview with JAMA Editor in Chief Kirsten Bibbins-Domingo and Virologist Davey Smith, head of the Division of Infectious Diseases and Global Public Health at the University of California, San Diego. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 5, 2024 Category: General Medicine Source Type: research